<DOC>
	<DOCNO>NCT02870569</DOCNO>
	<brief_summary>Donafenib advance 131I-refractory/resistant differentiated thyroid cancer ( DTC ) .</brief_summary>
	<brief_title>Phase 2 Trial Donafenib 131I-Refractory Differentiated Thyroid Cancer</brief_title>
	<detailed_description>This phase 2 study donafenib , oral multikinase inhibitor target Raf kinase receptor tyrosine kinase , assess efficacy safety patient 131I-refractory/resistant differentiated thyroid cancer.The study randomise , multicentre , open-label study .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Advanced metastasis thyroid cancer ; Subjects must histologically cytologically confirm diagnosis one following differentiate thyroid cancer ( DTC ) subtypes : papillary thyroid cancer ( PTC ) , follicular thyroid cancer ( FTC ) Hurthle cell ; Measurable disease meeting follow criterion confirm central radiographic review : 1 . At least 1 lesion great equal 1.0 cm long diameter nonlymph node great equal 1.5 cm shortaxis diameter lymph node serially measurable accord RECIST 1.1 use computerized tomography . 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must show evidence progressive disease base RECIST 1.1 deem target lesion ; 3 . Bone metastases lesion nonmeasurable . Subjects must show evidence disease progression within 14 month prior sign inform consent , accord RECIST 1.1 assess confirmed central radiographic review CT scan . Subjects must 131Irefractory / resistant define least one following : 1 . One measurable lesion demonstrate iodine uptake radioiodine scan 2 . One measurable lesion progress RECIST 1.1 within 14 month 131I therapy , despite demonstration radioiodine avidity time treatment pretreatment scan . 3 . Cumulative activity 131I &gt; 600 mCi 22 gigabequerels ( GBq ) , last dose administer least 6 month prior study entry Subjects may receive molecular target therapy ; Subjects know brain metastasis complete whole brain radiotherapy , stereotactic radiosurgery complete surgical resection , eligible remain clinically stable , asymptomatic steroid one month Subjects must tolerate thyroxin , TSH suppression ( TSH le 0.1 mU/mL ) ; Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0~2； Life expectancy least 3 month ; Adequate bone marrow function : 1 . Absolute neutrophil count ( ANC ) great equal 1500/mm3 ; 2 . Platelets great equal 100,000/mm3 ; 3 . Hemoglobin great equal 9.0g/dL Adequate blood coagulation function : 1 . Prothrombin time ( PT ) ≤17s ; 2 . Activated prothrombin time ( APTT ) ≤47s ; 3. International Normalized Ratio ( INR ) ≤2 . Adequate liver function : 1 . Bilirubin le equal 1.5 x upper limit normal ( ULN ) ; 2 . Alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 2.5 x upper limit normal ( ULN ) . All female must negative serum urine pregnancy test . Females childbearing potential male subject partner woman childbearing potential must use partner must use highly effective method contraception ; Voluntary provision write informed consent willingness ability comply aspects protocol . Anaplastic Medullary carcinoma thyroid ; Prior treatment sorafenib molecular target drug ; Subjects receive chemotherapy extra radiotherapy within 30 day prior first dose study drug recover toxicity relate previous anticancer treatment ; Major surgery within 30 day prior first dose study drug ; Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina ; myocardial infarction stroke within 6 month first dose study drug , cardiac arrhythmia require medical treatment ; Active infection ( infection require treatment ) ; Active malignancy ( except differentiate thyroid carcinoma , definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 24 month ; Known intolerance study drug ( excipients ) ; All chemotherapy radiationrelated toxicity must resolve less Grade 2 severity , except alopecia infertility ; Adequately control blood pressure without antihypertensive medication , define BP le 140/90 mmHg use least 2 kind medicine ; Adequate renal function define calculated creatinine clearance less equal 60 mL/min per Cockcroft Gault formula .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>